rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NVCR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      NovoCure (NVCR) Stock May Trade At A Discount Despite FDA Setback
      Nov 12Yahoo FinanceNVCR
      FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
      Nov 10Yahoo FinanceNVCR
      Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device
      Nov 9BenzingaNVCR
      US FDA declines to approve Novocure's lung cancer device
      Nov 9ReutersNVCR
      Novocure receives FDA rejection for brain cancer treatment
      Nov 9Investing.comNVCR
      NovoCure Earnings Call Signals Growth and Profitability Momentum

      Tipranks Press Release.

      Nov 3The Globe and MailNVCR
      Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
      Nov 2Yahoo FinanceNVCR
      NovoCure: 3 Key Takeaways for Long-Term Investors
      Nov 2Yahoo FinanceNVCR
      NovoCure (NVCR) Q3 Results Spark Margin Turn Debate
      Oct 31Yahoo FinanceNVCR
      NovoCure Stock Is In Focus After Earnings Beat And Slower Optune Pax Launch
      Oct 30Yahoo FinanceNVCR
      NovoCure Ltd (NVCR) (Q3 2026) Earnings Call Highlights: Record Revenue and First Positive ...
      Oct 29Yahoo FinanceNVCR
      NovoCure Q3 Earnings Call Highlights
      Oct 29Yahoo FinanceNVCR
      NovoCure (NVCR) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Oct 29The Globe and MailNVCR
      Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
      Oct 29Yahoo FinanceNVCR
      NovoCure Sinks 5% Despite Guidance Raise as Pancreatic Cancer Launch Access Is “Significantly Limited”
      Oct 29Yahoo FinanceNVCR
      NovoCure Shares Fall After Narrower Q3 Loss, Revenue Beat
      Oct 29Yahoo FinanceNVCR
      NovoCure Q3 2026 slides: record revenue, positive EBITDA milestone
      Oct 29Investing.comNVCR
      NovoCure Q3 2026 Earnings Call Transcript
      Oct 29BenzingaNVCR
      Earnings call transcript: NovoCure beats Q3 2026 estimates but shares fall premarket
      Oct 29Investing.comNVCR
      NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
      Oct 29Yahoo FinanceNVCR
      NovoCure: Q3 Earnings Snapshot
      Oct 29Yahoo FinanceNVCR
      Novocure Ltd earnings beat by $0.14, revenue topped estimates
      Oct 29Investing.comNVCR
      Novocure partners with Verastem on pancreatic cancer trial
      Oct 28Investing.comNVCRVSTM
      Novocure: A Mispriced Cash-Generating Biotech With Upside Potential (NASDAQ:NVCR)
      Oct 13Seeking AlphaNVCR
      The Bull Case For NovoCure (NVCR) Could Change Following Japan’s Optune Pax Pancreatic Cancer Approval
      Oct 10Yahoo FinanceNVCR
      NovoCure Gains Japanese Approval for Optune Pax Pancreatic Therapy

      Detailed price information for Novocure Ltd Ord Sh (NVCR-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailNVCR
      Novocure to Report Third Quarter 2026 Financial Results

      BAAR, Switzerland, October 01, 2026--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open.

      Oct 1Yahoo FinanceNVCR
      NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall

      NovoCure has seen its share price move around in recent years, and the stock now trades at US$16.67, which raises a straightforward question for investors: Is that level supported by what the business is generating in sales today and what the market expects those sales to become over time? Over the past 5 years the share price has fallen 86.1%, which puts the current valuation debate squarely on whether the remaining market value still lines up with the revenue base. The business model...

      Sep 23Yahoo FinanceNVCR
      NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change
      Sep 23Yahoo FinanceNVCR
      NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

      NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference. Chief Executive Officer Frank Leonard said the company, founded more th

      Sep 18Yahoo FinanceNVCR
      Novocure at Morgan Stanley conference: growth, discipline and expansion
      Sep 14Investing.comNVCRMS
      NovoCure at Wells Fargo healthcare conference: launch momentum builds
      Sep 9Investing.comNVCRWFC
      Novocure Reports Patient Data Exposure in Cybersecurity Incident

      NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.

      Sep 7Yahoo FinanceNVCR
      NovoCure says cyberattack caused patient data exposure
      Sep 3Yahoo FinanceNVCR
      Novocure Announces Upcoming Investor Events

      BAAR, Switzerland, September 02, 2026--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.

      Sep 2Yahoo FinanceNVCR
      Oncology firm Novocure says cyberattack exposed US patient records
      Sep 1ReutersNVCR
      NovoCure stock drops after cyberattack (NVCR:NASDAQ)

      NovoCure (NVCR) stock dips as the company discloses that a cybersecurity breach exposed limited patient and employee data. Read more here.

      Sep 1Seeking AlphaNVCR
      Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

      The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

      Aug 28Yahoo FinanceNVCR

      This is the newest page. Registered accounts read further back.